Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 51 CHF -0.97%
Market Cap: 618.2m CHF

Intrinsic Value

The intrinsic value of one BSLN stock under the Base Case scenario is 74.89 CHF. Compared to the current market price of 51 CHF, Basilea Pharmaceutica AG is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BSLN Intrinsic Value
74.89 CHF
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Basilea Pharmaceutica AG

What is Valuation History?
Ask AI Assistant
What other research platforms think about BSLN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BSLN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Basilea Pharmaceutica AG.

Explain Valuation
Compare BSLN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BSLN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Basilea Pharmaceutica AG

Current Assets 217.5m
Cash & Short-Term Investments 128.4m
Receivables 57.3m
Other Current Assets 31.8m
Non-Current Assets 31.4m
PP&E 17.5m
Intangibles 335k
Other Non-Current Assets 13.5m
Current Liabilities 34.4m
Accounts Payable 9.9m
Accrued Liabilities 19.4m
Other Current Liabilities 5.1m
Non-Current Liabilities 111.3m
Long-Term Debt 82m
Other Non-Current Liabilities 29.3m
Efficiency

Free Cash Flow Analysis
Basilea Pharmaceutica AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Basilea Pharmaceutica AG

Revenue
236.2m CHF
Cost of Revenue
-44.8m CHF
Gross Profit
191.4m CHF
Operating Expenses
-115.5m CHF
Operating Income
76m CHF
Other Expenses
-3.3m CHF
Net Income
72.7m CHF
Fundamental Scores

BSLN Profitability Score
Profitability Due Diligence

Basilea Pharmaceutica AG's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Exceptional ROIC
Exceptional 3Y Average ROIC
Exceptional ROE
ROIC is Increasing
75/100
Profitability
Score

Basilea Pharmaceutica AG's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

BSLN Solvency Score
Solvency Due Diligence

Basilea Pharmaceutica AG's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
64/100
Solvency
Score

Basilea Pharmaceutica AG's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 80.92 CHF with a low forecast of 64.64 CHF and a high forecast of 110.25 CHF.

Lowest
Price Target
64.64 CHF
27% Upside
Average
Price Target
80.92 CHF
59% Upside
Highest
Price Target
110.25 CHF
116% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BSLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one BSLN stock?

The intrinsic value of one BSLN stock under the Base Case scenario is 74.89 CHF.

Is BSLN stock undervalued or overvalued?

Compared to the current market price of 51 CHF, Basilea Pharmaceutica AG is Undervalued by 32%.

Back to Top